Earlier this month, Fox Chase Cancer Center became the first hospital in North America to offer an MRI guided biopsy to detect prostate cancer using Invivo Equipment in a clinical hospital setting. Pioneering new techniques for MRI-guided prostate interventions, Fox Chase is offering a new procedure for men with elevated prostate-specific antigen (PSA) levels who have had at least two negative transrectal ultrasound guided (TRUS) biopsies and whose doctors suspect cancer.
"Our first step is to take an endorectal coil MRI of the prostate with contrast enhancement," explains Barton N. Milestone, MD, a radiologist at Fox Chase, who was instrumental in bringing this technology to Fox Chase. "Next, computer-aided software helps identify abnormal areas as shown through the enhancement activity. If suspicious tissue is found, the patient is considered a candidate for MRI guided biopsy."
The MRI guided biopsy is used to target a specific area for sampling. It requires a needle guide to be inserted into the rectum next to the patient's prostate. Next, MR images are obtained, the abnormal area is identified, and a needle is inserted through the guide to the targeted area for tissue samples, which will later be examined for cancer.
"In a preliminary study in Europe, cancer was found in 59% of patients with two negative TRUS biopsies using this MRI technique," Milestone adds.
The device used to perform the MRI guided biopsy establishes its own frame of reference from an initial set of images. The endorectal MR images are used to locate suspicious areas in the prostate gland and then are correlated with the new images obtained at the time of biopsy for targeting. This type of biopsy requires less sampling because it is targeted. As with traditional biopsies, test results are typically available 3 days after the procedure is done.
|Contact: Lisa Bailey|
Fox Chase Cancer Center